Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or Click To Learn More >

IMBRUVICA® (ibrutinib) has helped many adults with CLL/SLL live longer

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love

here's to the life in your years


IMBRUVICA® is approved for multiple uses. Choose from below:

*In a clinical study of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.

Different from chemotherapy

IMBRUVICA® is an oral, once-daily medicine that works differently from chemotherapy.

Coverage and cost questions?

Understand your insurance coverage and potential financial support options.

Discover personalized one-on-one support

Get support when you need it with help from IMBRUVICA® By Your Side Ambassadors and communications.

Learn from a patient

Hear from a CLL patient about their experience with IMBRUVICA®

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at